Abstract: Methods for using hydroxyamino- and amino-substituted pyridine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of hydroxyamino- and amino-substituted pyridine analogs, are disclosed herein.
Type:
Grant
Filed:
December 19, 2006
Date of Patent:
January 11, 2011
Assignee:
Alcon Research, Ltd.
Inventors:
Hwang-Hsing Chen, Najam A. Sharif, Mark R. Hellberg
Abstract: An improved viscoelastic composition useful in the performance of ophthalmic surgical procedures and especially cataract procedures is disclosed. The embodiments of the composition comprise combinations of sodium hyaluronate and chondroitin sulfate and exhibit an improved rheological profile.
Type:
Grant
Filed:
September 30, 2004
Date of Patent:
October 26, 2010
Assignee:
Alcon, Inc.
Inventors:
Masoud R. Jafari, Kerry L. Markwardt, Uday Doshi
Abstract: Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.
Type:
Grant
Filed:
December 19, 2007
Date of Patent:
October 26, 2010
Assignee:
Alcon Research, Ltd.
Inventors:
Hwang-Hsing Chen, Andrew Rusinko, Mark R. Hellberg, Bryon S. Severns, Alan J. Henderson, Cheng Guo, Mark Hadden
Abstract: The present invention concerns a method for diagnosing or monitoring elevated intraocular pressure or glaucoma in a patient comprising providing a biological sample from the patient and measuring the expression level of a superoxide dismutase-2 (SOD-2) gene in the biological sample. The present invention also concerns methods for treating glaucoma or elevated intraocular pressure in a patient comprising administering to a patient an effective amount of an agent that modulates SOD-2 expression or SOD-2 activity.
Type:
Grant
Filed:
February 28, 2007
Date of Patent:
October 5, 2010
Assignee:
Alcon Research, Ltd.
Inventors:
Wan-Heng Wang, Loretta Graves McNatt, Abbot F. Clark, Peter G. Klimko
Abstract: Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines, are disclosed herein.
Type:
Grant
Filed:
December 19, 2006
Date of Patent:
February 2, 2010
Assignee:
Alcon Research, Ltd.
Inventors:
Mark R. Hellberg, Najam A. Sharif, Jesse A. May, Andrew Rusinko, Hwang-Hsing Chen
Abstract: Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.
Abstract: Disclosed are surface modified viscoelastics and methods of performing viscosurgery using polymer-containing irrigating solution to reduce cohesiveness of the viscoelastic agent at the interface, thereby improving its performance by reducing the occurrence of unintentional aspiration, especially in ocular surgery.
Abstract: A method of performing intra-articular therapy and a dilution resistant viscoelastic composition are disclosed. One embodiment of the dilution resistant composition comprises a hyaluronate-based viscoelastic agent and a low viscosity, polymer-containing solution. The hyaluronate-based viscoelastic can be an aqueous solution sodium hyaluronate having an average molecular weight greater than 750,000 Daltons and a concentration by weight between 0.5% and 3%. The polymer-containing solution can contain a polymer selected from the group consisting of chondroitin sulfate and hydroxypropylmethylcellulose. One embodiment can comprise a polymer-containing solution containing hydroxypropylmethylcellulose at a concentration by weight from about 0.05% to about 5.0% and chondroitin sulfate at a concentration by weight from about 0.1 to about 7%.
Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
Type:
Grant
Filed:
April 18, 2003
Date of Patent:
April 1, 2008
Assignee:
Alcon, Inc.
Inventors:
Debra L. Fleenor, Allan Shepard, Nasreen Jacobson, Iok-Hou Pang, Abbot F. Clark
Abstract: The use of inorganic nanoparticles to stabilize aqueous hydrogen peroxide solutions is described. The preferred nanoparticles are formed from clays. The use of nanoparticles formed from synthetic smectite clays is particularly preferred. The stabilized hydrogen peroxide solutions may be utilized for various purposes, but are particularly useful as contact lens disinfecting solutions.
Type:
Grant
Filed:
November 16, 2004
Date of Patent:
March 18, 2008
Assignee:
Alcon, Inc.
Inventors:
Howard Allen Ketelson, Nathaniel D. McQueen
Abstract: A new method of evaluating the ability of drug molecules to penetrate the cornea is described. The permeation rate of the drug molecules in MDCK cells is utilized to predict the ability of the molecules to penetrate the cornea. The method is useful for in vitro screening of potential new ophthalmic drugs, as well as in the design of new drug molecules for topical ocular administration.
Type:
Grant
Filed:
April 25, 2005
Date of Patent:
November 20, 2007
Assignee:
Alcon, Inc.
Inventors:
Andrew Rusinko, Mark R. Hellberg, Jesse Albert May, Geoffrey Robert Owen
Abstract: A viscoelastic composition for injection into a human eye comprised of about 2.0 to 2.5 percent of hydroxypropyl methylcellulose dissolved in a physiological salt solution, the composition, the composition having a viscosity from about 15,000 to about 40,000 centipoise and the hydroxypropyl methylcellulose having a molecular weight from about 220,000 to less than about 420,000 Daltons, the composition being free of debris or gels greater than 0.5 ?m. Also described is a process for preparing the clean, high molecular weight hydroxy propylmethyl cellulose composition.